Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

Kiniksa Pharmaceuticals Director Barry D. Quart sold 15,960 Class A Ordinary Shares for approximately $719,000 after exercising options.

Kiniksa Pharmaceuticals Director Richard S. Levy exercised 683 Restricted Share Units, converting them into Class A Ordinary Shares.

Kiniksa Pharmaceuticals International's CFO, Mark Ragosa, sold 12,000 Class A Ordinary Shares for a weighted average price of $41.89 per share under a Rule 10b5-1 plan.

Kiniksa Pharmaceuticals Director Barry D. Quart exercised options and subsequently sold 20,129 Class A Ordinary Shares for a significant profit under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, exercised stock options and subsequently sold a portion of his Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals CFO Mark Ragosa exercised stock options and subsequently sold a portion of his Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals COO Eben Tessari exercised options and immediately sold 200 Class A Ordinary Shares for a profit, as part of a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals COO Eben Tessari exercised options and subsequently sold a portion of Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, reported gifting Class A Ordinary Shares to family trusts.

Kiniksa Pharmaceuticals CFO Mark Ragosa exercised options and subsequently sold 19,900 Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Medical Officer, John F. Paolini, sold 82,542 Class A Ordinary Shares for a weighted average price of $37.14 per share, following the exercise of options, as part of a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International's Chief Financial Officer, Mark Ragosa, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals International's Chairman and CEO, Sanj K. Patel, executed pre-planned sales of Class A Ordinary Shares totaling 257,969 shares over three days in October 2025.

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, exercised stock options and subsequently sold a portion of his Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, reported the exercise of stock options and subsequent sale of Class A Ordinary Shares totaling 12,368 shares under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, reported the acquisition of 175 Class A Ordinary Shares from RSU vesting and the disposition of 85 shares for tax purposes.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, sold 42,000 Class A Ordinary Shares for a weighted average price of $38.33 after exercising options at $17.92.

Kiniksa Pharmaceuticals COO Eben Tessari sold a significant number of Class A Ordinary Shares on September 15, 2025, following the exercise of stock options, all under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, executed pre-planned transactions, exercising stock options and subsequently selling a portion of the acquired shares.

Kiniksa Pharmaceuticals' Chief Corporate & Commercial Officer, Ross Moat, sold 3,523 Class A Ordinary Shares for $35.31 each, executed under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, increased direct share ownership and received new equity grants, while executing pre-planned sales.

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, reported a series of equity transactions including RSU vestings, option exercises, and a pre-planned share sale.

Kiniksa Pharmaceuticals' Chief Corporate & Commercial Officer, Ross Moat, reported multiple equity transactions including RSU vesting, share option grants, and tax-related share disposals.

Kiniksa Pharmaceuticals' Chief Medical Officer, John F. Paolini, reported the acquisition of new equity awards and the exercise and sale of shares related to vesting.

Kiniksa Pharmaceuticals CFO Mark Ragosa reported the acquisition of new equity awards and the vesting of previous grants, alongside tax-related share dispositions.

Kiniksa Pharmaceuticals CEO Sanj K. Patel reported the acquisition of new equity awards and the exercise and sale of shares related to vesting and tax obligations.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, sold 16,200 Class A Ordinary Shares for approximately $547,000 after exercising options, as part of a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals director Thomas Malley executed a series of pre-planned stock option exercises and subsequent share sales, realizing significant gains.

Kiniksa Pharmaceuticals' Chief Medical Officer, John F. Paolini, sold 29,325 Class A Ordinary Shares for a weighted average price of $32.55 after exercising options at $3.80, as part of a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals COO Eben Tessari executed pre-planned transactions, acquiring shares via ESPP and option exercises while selling a portion of shares.